CHEK2 and glioblastoma: Therapies that inhibit CHK2 levels in GBM may enhance the efficacy of TRAIL treatment, hinting that DNA damage signaling pathways might contribute to TRAIL resistance and that targeting DNA repair factors is a strategy to overcome TRAIL resistance of GBM [104].